Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 30;26(11):5268.
doi: 10.3390/ijms26115268.

New Frontiers of Biomarkers in Metastatic Colorectal Cancer: Potential and Critical Issues

Bianca Medici  1 , Stefania Benatti  1 , Massimo Dominici  1 , Fabio Gelsomino  1
Affiliations
Review

New Frontiers of Biomarkers in Metastatic Colorectal Cancer: Potential and Critical Issues

Bianca Medici et al. Int J Mol Sci. .

Abstract

Metastatic colorectal cancer (mCRC) remains a major cause of cancer-related mortality worldwide and requires the development of new biomarkers to improve patient management. Traditional markers, such as RAS mutations and microsatellite instability (MSI), have revolutionized therapeutic decisions, but emerging evidence underlines the importance of integrating multi-omics sciences for a deeper understanding of tumor biology and therapeutic resistance. Although these omics technologies hold great promise for the advancement of precision oncology, significant challenges remain. However, the integration of multi-omics data is opening the way to more accurate diagnostics, personalized therapies, and improved outcomes for mCRC patients. This review provides an in-depth description of the various omics sciences and explores their advantages and critical issues.

Keywords: metastatic colorectal cancer; multi-omics sciences; personalized therapies.

PubMed Disclaimer

Conflict of interest statement

F.G. received honoraria for speaker/advisory roles from Servier, Eli Lilly, Iqvia, Merck Serono, Amgen, and Bristol-Myers Squibb outside the present work. The other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Omics sciences in colorectal cancer. CTC: circulating tumor cells; ctDNA: circulating tumor DNA; ncRNAs: non-coding RNAs. The figure was created by BioRender online software (BioRender.com accessed on 7 May 2025).
See this image and copyright information in PMC

References

    1. Das V., Kalita J., Pal M. Predictive and Prognostic Biomarkers in Colorectal Cancer: A Systematic Review of Recent Advances and Challenges. Biomed. Pharmacother. 2017;87:8–19. doi: 10.1016/j.biopha.2016.12.064. - DOI - PubMed
    1. Koncina E., Haan S., Rauh S., Letellier E. Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges. Cancers. 2020;12:319. doi: 10.3390/cancers12020319. - DOI - PMC - PubMed
    1. Erstad D.J., Tumusiime G., Cusack J.C. Prognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon. Ann. Surg. Oncol. 2015;22:3433–3450. doi: 10.1245/s10434-015-4706-x. - DOI - PubMed
    1. Ren H., Shen X., Xie M., Guo X. Construction of a Prognostic Score Model for Breast Cancer Based on Multi-Omics Analysis of Study on Bone Metastasis. Transl. Cancer Res. 2024;13:2419–2436. doi: 10.21037/tcr-23-1881. - DOI - PMC - PubMed
    1. Donisi C., Pretta A., Pusceddu V., Ziranu P., Lai E., Puzzoni M., Mariani S., Massa E., Madeddu C., Scartozzi M. Immunotherapy and Cancer: The Multi-Omics Perspective. IJMS. 2024;25:3563. doi: 10.3390/ijms25063563. - DOI - PMC - PubMed

Substances

LinkOut - more resources